Carregant...
Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database
BACKGROUND: Vascular endothelial growth factor (VEGF), tyrosine kinase (TK) and mechanistic target of rapamycin kinase (mTOR) inhibitors are common first-line (1 L) treatments for metastatic renal cell carcinoma (mRCC). Despite treatment availability, the 5-year survival rate in patients diagnosed a...
Guardat en:
| Publicat a: | BMC Cancer |
|---|---|
| Autors principals: | , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6555983/ https://ncbi.nlm.nih.gov/pubmed/31174493 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5716-z |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|